Amerise Biosciences Ltd

Amerise Biosciences Limited announced that its Board of Directors, in a meeting held on October 30, 2026, approved the un-audited financial results for the quarter and half-year ended September 30, 2026. The board meeting commenced at 3:45 PM and concluded at 4:15 PM. The statutory auditors have carried out a limited review of these financial results. The company operates in a single segment.

Snehjeev Ventures Pvt Ltd, along with persons acting in concert, has acquired 8,603,076 equity shares of Amerise Biosciences Ltd. This acquisition represents a 13.02% stake in the company. The transaction was executed via the open market. The total equity share capital of Amerise Biosciences Ltd. is Rs. 6,60,69,000/-.

Amerise Biosciences Ltd has announced an update to its official website. The new website address is www.amerisebiosciencesltd.bar. The company has requested that all stakeholders update their records with this new URL and remove any previous website details. This change is for informational purposes and to ensure accurate contact information.

Amerise Biosciences Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from Thursday, October 1st, 2026, and will reopen 48 hours after the announcement of the unaudited financial results for the second quarter ended September 30th, 2026. The specific date for the board meeting to consider these results will be communicated later.

Amerise Biosciences Limited (formerly Amradeep Industries Limited) has announced its 41st Annual General Meeting (AGM) to be held on Thursday, September 24, 2026, at 3:00 PM in Ahmedabad. The meeting agenda includes the adoption of audited financial statements for the year ended March 31, 2026, and the reports of the Board of Directors and Auditors. A key item of special business is the proposed appointment of Mr. Albert Hines as Whole Time Director and Chief Financial Officer (CFO) effective February 2, 2026, for a period of three years, with nil remuneration. The company also provided details regarding proxy appointments, authorized representatives, and closure of the Register of Members.

Amerise Biosciences Ltd has announced its 41st Annual General Meeting (AGM) to be held on Thursday, September 24, 2026. The meeting will take place at the company's registered office in Ahmedabad. Key agenda items include the adoption of the audited financial statements for the fiscal year 2025-26, along with the reports of the Board of Directors and Auditors. Additionally, the members will vote on the appointment of Mr. Albert Hines as Whole-Time Director and Chief Financial Officer (CFO) for a period of three years, commencing February 2, 2026, with nil remuneration. The filing also includes the Notice of the AGM and the Annual Report for the financial year 2025-26.

Snehjeev Ventures Pvt Ltd, along with Persons Acting in Concert (PACs), has disclosed the acquisition of 7,292,684 equity shares in Amerise Biosciences Ltd. This acquisition represents a holding of 11.04% of the total capital of the target company as of August 14, 2026. The shares were acquired through the open market. Prior to this acquisition, the acquirer and PACs held 10.92% of the company's shares. The disclosure is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Amerise Biosciences Ltd announced that its Board of Directors has approved the un-audited standalone financial results for the quarter ended June 30, 2026. The board meeting took place on August 3, 2026. The financial results were reviewed by the Audit Committee and approved by the Board. The Statutory Auditors have carried out a limited review. The company operates in a single segment.

Amerise Biosciences Ltd announced that its Board of Directors, in a meeting held on August 3, 2026, considered and approved the un-audited standalone financial results for the quarter ended June 30, 2026. The meeting commenced at 04:50 PM and concluded at 05:10 PM. The financial results have been reviewed by the Audit Committee and approved by the Board. The Statutory Auditors have also carried out a limited review. The company operates in a single segment.

Amerise Biosciences Ltd announced that its Board of Directors, in a meeting held on August 3, 2026, approved the un-audited financial results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and have undergone a limited review by the statutory auditors. The company operates in a single segment. The board meeting commenced at 04:50 PM and concluded at 05:10 PM.